Xencor, Inc. (NASDAQ: XNCR), a biopharmaceutical firm focused on developing engineered antibodies for cancer and autoimmune diseases, has scheduled a conference call and webcast for October 24, at 1:30 p.m. ET (10:30 a.m. PT). The event aims to discuss the preliminary findings from the ongoing Phase 1 dose-escalation study of XmAb819, a bispecific antibody designed to engage T-cells against advanced clear cell renal cell carcinoma (ccRCC). This innovative therapy targets the ENPP3 antigen, which is predominantly expressed in kidney cancers, and aims to enhance the immune response against tumor cells.
The live presentation will be accessible via a dedicated link and through the “Events & Presentations” section of the Xencor website, allowing interested parties to participate actively. A recorded version of the call will be available for at least 30 days following the event, ensuring stakeholders have access to the critical information shared during the discussion.
### Upcoming Presentation at Key Conference
The results from the Phase 1 study will also be highlighted during the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics, which will take place in Boston, Massachusetts. A poster entitled “Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)” will be presented as part of Poster Session B on the same day from 12:30 to 4:00 p.m. ET. This presentation will provide a platform for disseminating findings to researchers and clinicians in the oncology space.
### Overview of XmAb819 Development
XmAb819 represents a pioneering approach in cancer therapy as a tumor-targeted, T-cell-engaging bispecific antibody. Its design allows for a robust immune response by targeting both the ENPP3 antigen, which is highly expressed in renal cell carcinoma, and engaging T-cells to selectively destroy tumor cells. The dual targeting mechanism is intended to maximize the effectiveness of the treatment while minimizing damage to normal tissues.
Xencor is committed to advancing innovative therapies and has over 20 candidates in clinical development, showcasing its dedication to addressing unmet medical needs in oncology and autoimmune diseases. The company leverages its proprietary XmAb engineering technology to create novel therapeutic mechanisms, underscoring its role as a leader in the biopharmaceutical landscape.
As the clinical trial progresses, Xencor emphasizes the potential of XmAb819 to offer new hope for patients battling advanced kidney cancer, aligning its research efforts with the pressing demand for effective cancer treatments. Stakeholders are encouraged to monitor the outcomes of the upcoming presentations for more insights into the efficacy and safety of this promising therapy.
Related
